


MONJUVI[®]
 tafasitamab-cxix | 200mg
 for injection, for intravenous use

ANNOUNCING A
UNIQUE J-CODE
 FOR MONJUVI:
J9349

Injection, tafasitamab-cxix, 2mg
 EFFECTIVE **APRIL 1, 2021**



USING J9349 MAY HELP WITH MORE TIMELY REIMBURSEMENT

HCPCS Code	J9349
Effective Date	April 1, 2021
J-Code Descriptor	Injection, tafasitamab-cxix, 2mg
Single-Dose Vial Size	200mg
Billing Unit Conversion	One 200mg Single-Dose Vial = 100 Units



If date of service occurred before April 1, 2021, check with payers to determine appropriate coding.



For Billing and Coding or Reimbursement Questions, or to Request Support From a Member of the Field Access and Reimbursement Team, Call 855-421-6172, M-F 8 AM to 8 PM ET

The information herein is provided for educational purposes only. MorphoSys and Incyte cannot guarantee insurance coverage or reimbursement. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.

HCPCS – Healthcare Common Procedure Coding System.

MONJUVI and the MONJUVI logo are registered trademarks of MorphoSys AG.
 © 2021 MorphoSys US February 2021 RC-US-TAF-00731
 Distributed and marketed by MorphoSys US Inc. and marketed by Incyte Corp.
 MorphoSys is a registered trademark of MorphoSys AG.
 Incyte and the Incyte logo are registered trademarks of Incyte Corp.

